JP2021523894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021523894A5 JP2021523894A5 JP2020562124A JP2020562124A JP2021523894A5 JP 2021523894 A5 JP2021523894 A5 JP 2021523894A5 JP 2020562124 A JP2020562124 A JP 2020562124A JP 2020562124 A JP2020562124 A JP 2020562124A JP 2021523894 A5 JP2021523894 A5 JP 2021523894A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- patient
- antagonist
- pharmaceutical composition
- canakinumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 41
- 239000005557 antagonist Substances 0.000 claims description 30
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 28
- 229960001838 canakinumab Drugs 0.000 claims description 25
- 102100032752 C-reactive protein Human genes 0.000 claims description 8
- 230000002411 adverse Effects 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000011882 arthroplasty Methods 0.000 description 3
- 238000011883 total knee arthroplasty Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034283A JP7713983B2 (ja) | 2018-05-09 | 2023-03-07 | カナキヌマブの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669071P | 2018-05-09 | 2018-05-09 | |
| US62/669,071 | 2018-05-09 | ||
| PCT/IB2018/056455 WO2019215484A1 (en) | 2018-05-09 | 2018-08-24 | Use of canakinumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034283A Division JP7713983B2 (ja) | 2018-05-09 | 2023-03-07 | カナキヌマブの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523894A JP2021523894A (ja) | 2021-09-09 |
| JP2021523894A5 true JP2021523894A5 (https=) | 2021-10-21 |
Family
ID=63638190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562124A Withdrawn JP2021523894A (ja) | 2018-05-09 | 2018-08-24 | カナキヌマブの使用 |
| JP2023034283A Active JP7713983B2 (ja) | 2018-05-09 | 2023-03-07 | カナキヌマブの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034283A Active JP7713983B2 (ja) | 2018-05-09 | 2023-03-07 | カナキヌマブの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210371511A1 (https=) |
| EP (1) | EP3790576A1 (https=) |
| JP (2) | JP2021523894A (https=) |
| KR (1) | KR20210008847A (https=) |
| CN (2) | CN119746057A (https=) |
| AU (1) | AU2018422406A1 (https=) |
| BR (1) | BR112020022576A2 (https=) |
| CA (1) | CA3098277A1 (https=) |
| CL (1) | CL2020002881A1 (https=) |
| MX (1) | MX2020011909A (https=) |
| TW (1) | TW201946652A (https=) |
| WO (1) | WO2019215484A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| TR201802449T4 (tr) * | 2005-10-26 | 2018-03-21 | Novartis Ag | Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi. |
| MX362591B (es) * | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| BR112014007253A2 (pt) | 2011-09-30 | 2017-03-28 | Novartis Ag | uso de anticorpos que se ligam a il-1beta |
| WO2015084883A2 (en) * | 2013-12-02 | 2015-06-11 | Abbvie, Inc. | Compositions and methods for treating osteoarthritis |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| JP2020524694A (ja) * | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| CN107723310B (zh) * | 2017-10-19 | 2024-01-09 | 北京睿诚海汇健康科技有限公司 | 植物作为宿主在表达卡那抗体中的应用 |
-
2018
- 2018-08-24 TW TW107129705A patent/TW201946652A/zh unknown
- 2018-08-24 KR KR1020207035003A patent/KR20210008847A/ko not_active Withdrawn
- 2018-08-24 AU AU2018422406A patent/AU2018422406A1/en not_active Abandoned
- 2018-08-24 WO PCT/IB2018/056455 patent/WO2019215484A1/en not_active Ceased
- 2018-08-24 EP EP18772905.8A patent/EP3790576A1/en active Pending
- 2018-08-24 MX MX2020011909A patent/MX2020011909A/es unknown
- 2018-08-24 BR BR112020022576-2A patent/BR112020022576A2/pt not_active IP Right Cessation
- 2018-08-24 CA CA3098277A patent/CA3098277A1/en not_active Abandoned
- 2018-08-24 CN CN202411634666.2A patent/CN119746057A/zh active Pending
- 2018-08-24 CN CN201880094285.6A patent/CN112584857A/zh active Pending
- 2018-08-24 US US17/053,602 patent/US20210371511A1/en active Pending
- 2018-08-24 JP JP2020562124A patent/JP2021523894A/ja not_active Withdrawn
-
2020
- 2020-11-06 CL CL2020002881A patent/CL2020002881A1/es unknown
-
2023
- 2023-03-07 JP JP2023034283A patent/JP7713983B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505486A5 (https=) | ||
| Bartl et al. | Treatment of bone marrow edema syndrome with intravenous ibandronate | |
| Peters et al. | Colchicine in the treatment of pulmonary fibrosis | |
| Iolascon et al. | The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies | |
| AU2015230986A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| EP3370721A1 (en) | Treatment of osteoarthritis | |
| JP2017160178A5 (https=) | ||
| Pazzola et al. | Case report Tocilizumab in glucocorticoid-naïve large-vessel vasculitis | |
| van Meegeren et al. | Joint distraction results in clinical and structural improvement of haemophilic ankle arthropathy: a series of three cases | |
| WO2020236636A1 (en) | Methods of treating a mk2-mediated disorder | |
| JP2020535149A5 (https=) | ||
| KR20140025314A (ko) | 복합 조성물 | |
| JP2014515747A5 (https=) | ||
| Lee et al. | The 2024 Guidelines for Osteoporosis-Korean Society of Menopause: Part II | |
| ECSP055961A (es) | Formulaciones parenterales de péptidos para el tratamiento de lupus eritematoso sistémico | |
| Markatseli et al. | Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study | |
| JP2021523894A5 (https=) | ||
| Zhao et al. | The off-label uses profile of tofacitinib in systemic rheumatic diseases | |
| JP2019507786A5 (https=) | ||
| JP2014522414A5 (https=) | ||
| McKenna | Efficacy of diclofenac/misoprostol vs diclofenac in the treatment of ankylosing spondylitis | |
| Monaca-Charley et al. | Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis | |
| Santiago et al. | Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. | |
| Frieze | Musculoskeletal pain associated with corticosteroid therapy in cancer | |
| Schapira et al. | Successful pamidronate treatment of severe and refractory regional migratory osteoporosis |